Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Griffin

Sports Medicine Tulsa, OK Medical Doctor

NPI 1720306277 CMS profile 867795

4802 S 109Th East Ave, Tulsa, OK 74146

Open in the dashboard

General payments

$17,473

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Griffin of Tulsa, OK is reported in the CMS Open Payments database as having received $17,473 across 117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 67th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,453 16
2024 General $510 13
2023 General $954 16
2022 General $4,309 19
2021 General $7,499 15
2020 General $335 9
2019 General $2,412 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Griffin
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Jason Griffin were reported at $1,453. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Jason Griffin Sports Medicine median Middle half National median
2019 $2,412 $1,176 $199–$4,249 $163
2020 $335 $708 $96–$2,890 $114
2021 $7,499 $1,213 $152–$3,994 $132
2022 $4,309 $1,230 $159–$3,998 $149
2023 $954 $584 $146–$2,836 $160
2024 $510 $628 $163–$3,168 $164
2025 $1,453 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pylant Medical $10,232 22 payments
  2. Arthrex, Inc. $4,588 27 payments
  3. Smith+Nephew, Inc. $867 14 payments
  4. Stryker Corporation $355 9 payments
  5. Aesculap Biologics, LLC $225 3 payments
  6. Bioventus LLC $220 5 payments
  7. Miach Orthopaedics, Inc. $194 1 payment
  8. Flexion Therapeutics, Inc. $144 8 payments
  9. Ferring Pharmaceuticals Inc. $126 8 payments
  10. Bodycad USA Corp $112 1 payment
  11. Other $410 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $12,482 10 payments
  2. Food and Beverage $3,596 102 payments
  3. Travel and Lodging $1,394 5 payments
Products named General payments · program years 2019–2025
  1. Regeneten $297 4 payments
  2. NOVOCART 3D $225 3 payments
  3. HEALICOIL $180 4 payments
  4. XCELL $150 1 payment
  5. NOVOSTITCH $149 2 payments
  6. HEALICOIL REGENESORB $148 1 payment
  7. FIRSTPASS MINI $148 1 payment
  8. Bioinductive Implant with Arthroscopic Delivery System - Medium $144 1 payment
  9. Zilretta $144 8 payments
  10. ALPHAVENT $136 2 payments
  11. Other $1,527 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

65

Median for Orthopedic Surgery: 203

Drug cost

$417

Median for Orthopedic Surgery: $1,433

Branded share of claims

23.1%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 20 $140
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $121
Methocarbamol Generic 13 $93
Meloxicam Generic 17 $62

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$91,592

Of which drugs: $31,947

Medicare patients

158

Average age 71

Services billed

4,294

76 women, 82 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Diabetes 20%
Ischemic heart disease 20%
Depression 15%
Chronic kidney disease 12%
Cancer 12%
Atrial fibrillation 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 13 928 $12,441
Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 Office 20 1,800 $9,328
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 12 17 $9,180
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 90 700 $476

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record